Recent News and Webcasts:
Welcome to Inhibitex.com
The acquisition of Inhibitex by Bristol-Myers Squibb was completed February 14, 2012. For more information about Bristol-Myers Squibb, click here.
Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative
products that can treat or prevent serious infections. We are applying our expertise in the development
of a portfolio of high-value, differentiated infectious disease therapies. Our
pipeline addresses significant viral and bacterial infections, including herpes zoster
(shingles), chronic hepatitis C, and S. aureus infections.
